I’m still in both Joe and I’m of the opinion that whatever unfolds between Relief and NRXP NeuroRX won’t get less of a slice of pie than what they initially agreed upon. I believe both companies will rise but Relief has more things going for it in the coming months and years. An approval for Aviptadil will be a grand slam for both companies .
Currently, nine clinical trials are on the list (two of them in India), where Aviptadil is being tried via both the inhalational and intravenous route and tested subsequently based on some outcome parameters to assess the safety and efficacy of the drug in comparison to the use of placebo/Remdesivir/Monoclonal antibody and other immunosuppressants in treatment of COVID 19 disease complicated with severe respiratory failure. The details of those trials are summarized in [Table 2]. Among those 9 trials, 7 of them are in the recruitment stage comprising the trial with maximum sample size, where one trial is completed and the data of the remaining one has been made available recently.{Table 2}
Market Data 
Markets 
AI
